Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6 Pt 2
|
| pubmed:dateCreated |
1998-12-11
|
| pubmed:abstractText |
Approximately 25% of radical prostatectomies performed for stage T1c disease show potentially insignificant prostate cancer. We previously reported the use of serum prostate specific antigen (PSA) density and needle biopsy findings to predict potentially insignificant cancer. We now evaluate whether using free/total serum PSA levels along with needle biopsy findings can better predict tumor significance.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0022-5347
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
160
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2407-11
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:9817393-Biopsy, Needle,
pubmed-meshheading:9817393-Humans,
pubmed-meshheading:9817393-Male,
pubmed-meshheading:9817393-Neoplasm Staging,
pubmed-meshheading:9817393-Palpation,
pubmed-meshheading:9817393-Predictive Value of Tests,
pubmed-meshheading:9817393-Prostate-Specific Antigen,
pubmed-meshheading:9817393-Prostatic Neoplasms
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings.
|
| pubmed:affiliation |
Department of Urology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland 21287, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Review,
Research Support, Non-U.S. Gov't
|